K. Abe

Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumor.

A. Shilatifard, L. Zou, A. Piunti, 2022, Molecular cancer therapeutics.

Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma.

P. Zhang, A. Suri, R. Hashizume, 2022, Journal of neurosurgery.

BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma

Yukitomo Ishi, M. Natsumeda, Takahiro Sasaki, 2024, The Journal of clinical investigation.

Ataxia-telangiectasia mutated (Atm) disruption sensitizes spatially-directed H3.3K27M/TP53 diffuse midline gliomas to radiation therapy

Zachary J. Reitman, Joshua A Regal, Emily Hocke, 2023, bioRxiv.

Tissue-specific reprogramming leads to angiogenic neutrophil specialization and tumor vascularization in colorectal cancer

M. Schipma, P. Dulai, R. Sumagin, 2024, The Journal of clinical investigation.